Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Making cancer cells susceptible to therapeutic attack

23.08.2002


A researcher at the University of Illinois at Chicago College of Medicine is discovering how a gene known as E1A, found in a virus responsible for the common cold, renders tumor cells vulnerable to destruction.



"By explaining how E1A works, we hope to develop novel strategies to make human immunological defenses against tumors, as well as chemotherapy and radiation therapy, more effective in combating cancer," said Dr. James Cook, chief of infectious diseases and a member of the UIC Cancer Center.

The latest study is published in the July 23 issue of the Proceedings of the National Academy of Sciences.


To date, Cook and his colleagues have tested the E1A gene in cancer cells from four species: hamsters, mice, rats and humans. In all four cases, E1A renders the malignancies susceptible to defender cells of the immune system.

"We believe that these observations may reveal a common Achilles heel of many types of cancer cells," Cook said.

According to Cook, the goal is to find ways to make standard treatments for cancer more effective. Although the disease may respond to the first course of chemotherapy or radiation, typically tumor cells become more resistant later on, when the cancer recurs or metastasizes. The reasons are not clear.

Possibly, series of mutations are acquired as the tumor grows, yielding a naturally selected population of cells capable of thwarting killing agents. The standard clinical course is to change the drug or radiation strategy, but that may not be feasible or useful.

As an alternative, based on the studies Cook is undertaking, physicians may one day be able to alter the resistant malignant tissue itself, making it vulnerable to therapy.

"E1A is helping us identify the set of cellular switches that need to be turned on or off to render cancer cells more sensitive to therapeutic injury," Cook said.

In the present study, Cook and his colleagues examined a chain of molecular events that occur when cancer cells are confronted with one of the battery of chemicals produced by the immune system. The laboratory experiment mimicked what happens when a tumor begins to grow and the immune system tries to destroy the malignancy.

The chemical used in the study, called tumor necrosis factor, is manufactured primarily by macrophages, which are among the first cells on the scene in an immune response to tumors. When tumor necrosis factor attaches to receptors on the surface of a malignant cell, preparing the way for a full-scale attack, the cancer cell typically blocks the assault.

But when the E1A gene is inserted in the malignant cells, it shuts down the tumor’s defense mechanism. Cook showed that one key step in foiling the defense occurs when E1A gene products bind to cellular retinoblastoma proteins -- proteins that normally regulate a cell’s life cycle.

The finding suggests that the E1A gene renders malignant cells susceptible to attack not by interfering with their physiological functioning, but by preventing their use of normal cellular machinery to avoid destruction by the body’s immune defenses.

"Multiple molecular mechanisms triggered by E1A prevent tumor cells from thwarting an immunological attack," Cook said. "Further definition of these mechanisms will help us develop new concepts that may be useful for treating cancer, in part by enlisting the body to become a more active partner in fighting the disease."

Sharon Butler | EurekAlert!
Further information:
http://www.uic.edu/
http://www.uic.edu/com/cancer

More articles from Health and Medicine:

nachricht How cancer metastasis happens: Researchers reveal a key mechanism
19.01.2018 | Weill Cornell Medicine

nachricht Researchers identify new way to unmask melanoma cells to the immune system
17.01.2018 | Duke University Medical Center

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Artificial agent designs quantum experiments

On the way to an intelligent laboratory, physicists from Innsbruck and Vienna present an artificial agent that autonomously designs quantum experiments. In initial experiments, the system has independently (re)discovered experimental techniques that are nowadays standard in modern quantum optical laboratories. This shows how machines could play a more creative role in research in the future.

We carry smartphones in our pockets, the streets are dotted with semi-autonomous cars, but in the research laboratory experiments are still being designed by...

Im Focus: Scientists decipher key principle behind reaction of metalloenzymes

So-called pre-distorted states accelerate photochemical reactions too

What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...

Im Focus: The first precise measurement of a single molecule's effective charge

For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.

Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...

Im Focus: Paradigm shift in Paris: Encouraging an holistic view of laser machining

At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.

No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...

Im Focus: Room-temperature multiferroic thin films and their properties

Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.

Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

10th International Symposium: “Advanced Battery Power – Kraftwerk Batterie” Münster, 10-11 April 2018

08.01.2018 | Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

 
Latest News

Let the good tubes roll

19.01.2018 | Materials Sciences

How cancer metastasis happens: Researchers reveal a key mechanism

19.01.2018 | Health and Medicine

Meteoritic stardust unlocks timing of supernova dust formation

19.01.2018 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>